GleamWall
中文EN

HOWL Werewolf Therapeutics, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1785530 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY61.4%
TTM EPS YoY63.7%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-154.6%
ROA-46.0%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets84.2%
Debt / equity0.00x
Current ratio1.19x
Interest coverage-7.97x

Cash quality & payout

Operating cash flow / net income0.85x
Accruals ratio-6.8%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue——
R&D expense$44.83M$56.43M
SG&A expense$15.85M$19.05M
Operating income-$60.68M-$73.59M
Interest expense$5.27M$4.66M
Income tax$0—
Net income-$60.82M-$70.52M
EBITDA-$59.04M-$71.78M
EPS (basic)-1.32-1.63
EPS (diluted)-1.33-1.63
Weighted avg. shares (diluted)46.81M43.86M
Balance sheet
Cash & equivalents$57.05M$112.22M
Current assets$58.59M$113.07M
PP&E, net$4.69M$6.32M
Total assets$69.40M$126.93M
Current liabilities$36.15M$15.18M
Long-term debt$32.09M$32.09M
Total debt$32.09M$32.09M
Total liabilities$44.59M$53.54M
Shareholders' equity$24.80M$73.39M
Net debt-$24.96M-$80.13M
Shares outstanding48.60M44.83M
Cash flow statement
Operating cash flow-$60.29M-$56.19M
Capital expenditure$0$254,000
Free cash flow-$60.29M-$56.44M
Investing cash flow$0-$254,000
Financing cash flow$6.03M$13.08M
Depreciation & amortization$1.63M$1.81M
Stock-based compensation$6.25M$8.83M

Free plan shows the latest 2 periods; Pro shows all 6 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.